What is the current stock price of CG Oncology, Inc. Common stock (CGON)?

As of the latest market data, CG Oncology, Inc. Common stock (CGON) is trading at $67.70. The stock has seen a loss of -1.25% today.

Does CG Oncology, Inc. Common stock (CGON) pay a dividend?

Based on current data, CG Oncology, Inc. Common stock does not have a confirmed active dividend policy.

What is the market cap of CG Oncology, Inc. Common stock?

The current market capitalization of CG Oncology, Inc. Common stock (CGON) is approximately unavailable.

CGON

CG Oncology, Inc. Common stock·Healthcare

67.70

1.254%(−0.86)

Market Closed

76.90

13.589%(+9.20)

After Hours

Last Updated: — ET

52W L: $19.4752W H: $71.90

CGON NEWS

defenseworld.net

Mar 30

CG Oncology, Inc. $CGON Stake Lifted by JPMorgan Chase & Co.

JPMorgan Chase and Co. boosted its stake in CG Oncology, Inc. (NASDAQ: CGON) by 321.3% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 227,879 shares of the company's stock after buying an additional 173,785 shares during the period. JPMorgan

fool.com

Mar 21

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know

Kynam Capital sold 1,059,375 shares of CG Oncology in the fourth quarter; the estimated trade size was $43.84 million based on quarterly average prices. Meanwhile, the quarter-end position value decreased by $41.50 million, reflecting both trading activity and price movement.

defenseworld.net

Mar 20

CG Oncology (CGON) Expected to Announce Quarterly Earnings on Friday

CG Oncology (NASDAQ: CGON - Get Free Report) is anticipated to announce its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($0.61) per share for the quarter. Investors can check the company's upcoming Q4 2025 earning summary page for the latest details on the call

defenseworld.net

Mar 16

ArrowMark Colorado Holdings LLC Has $10.36 Million Holdings in CG Oncology, Inc. $CGON

ArrowMark Colorado Holdings LLC cut its position in CG Oncology, Inc. (NASDAQ: CGON) by 12.2% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 257,230 shares of the company's stock after selling 35,776 shares during the quarter. ArrowMark Colorado Holdings

defenseworld.net

Mar 13

Reviewing CG Oncology (NASDAQ:CGON) and CollPlant Biotechnologies (NASDAQ:CLGN)

CollPlant Biotechnologies (NASDAQ: CLGN - Get Free Report) and CG Oncology (NASDAQ: CGON - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability. Earnings and Valuation This table compares CollPlant Biotechnologies

defenseworld.net

Mar 5

CG Oncology (NASDAQ:CGON) vs. Adhera Therapeutics (OTCMKTS:ATRX) Critical Survey

CG Oncology (NASDAQ: CGON - Get Free Report) and Adhera Therapeutics (OTCMKTS:ATRX - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership. Analyst Recommendations This is a summary of current

Company Profile

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

Sector

Healthcare

Industry

Biotechnology

Employees

113

IPO Date

2024-01-25

Beta

0.70

Websitecgoncology.com↗